Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Ju Hee | - |
dc.contributor.author | Kim, Woojin | - |
dc.contributor.author | Kim, Yun Tae | - |
dc.contributor.author | Cho, Jaelim | - |
dc.contributor.author | Shin, Seung Yong | - |
dc.contributor.author | Kim, Changsoo | - |
dc.contributor.author | Kim, Jin-Bae | - |
dc.date.accessioned | 2023-03-08T07:44:49Z | - |
dc.date.available | 2023-03-08T07:44:49Z | - |
dc.date.issued | 2022-04 | - |
dc.identifier.issn | 2297-055X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/61436 | - |
dc.description.abstract | BackgroundSeveral studies have shown the cost-effectiveness of direct oral anticoagulants (DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications. However, few have reported cost-effectiveness of DOACs in AF patients with intermediate stroke risk. Thus, we investigated the cost-effectiveness of DOACs vs. warfarin in non-valvular AF patients with intermediate stroke risk using national representative data. MethodsWe identified 7,954 newly diagnosed non-valvular AF patients (>= 18 years) with intermediate stroke risk (CHA(2)DS(2)-VASc score: 1 for men and 2 for women) using the national healthcare utilization data from August 1, 2016, to July 31, 2019. Annual incidence rate of AF-related composite outcomes (heat failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, and gastrointestinal bleeding) was estimated. Cost-effectiveness was estimated using a Markov chain model with the transition probability of 1 year. The willingness-to-pay (WTP) was set at $32,000 per quality-adjusted life-year (QALY) gained. ResultsThe total cost of warfarin, rivaroxaban, apixaban, dabigatran and edoxaban was $2,874, $5,761, $5,151, $5,761 and $5,851, respectively. The QALYs gained were 10.83, 10.95, 11.10, 10.49 and 10.99 years, respectively. The incremental cost-effectiveness ratio of rivaroxaban, apixaban, dabigatran and edoxaban was $29,743.99, $8,426.71, -$8,483.04 and $18,483.55, respectively. The WTP was set at $32,000. DOACs (except dabigatran) were more cost-effective compared with warfarin because they did not exceed the WTP in the base-case analysis. ConclusionOur findings showed that DOACs were more cost-effective than warfarin in non-valvular AF patients with intermediate stroke risk. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk | - |
dc.type | Article | - |
dc.identifier.doi | 10.3389/fcvm.2022.849474 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN CARDIOVASCULAR MEDICINE, v.9 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000792391600001 | - |
dc.identifier.scopusid | 2-s2.0-85138521266 | - |
dc.citation.title | FRONTIERS IN CARDIOVASCULAR MEDICINE | - |
dc.citation.volume | 9 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | atrial fibrillation | - |
dc.subject.keywordAuthor | cost-effectiveness | - |
dc.subject.keywordAuthor | anticoagulants | - |
dc.subject.keywordAuthor | warfarin | - |
dc.subject.keywordAuthor | intermediate stroke risk | - |
dc.subject.keywordPlus | CLINICAL-FEATURES | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | APIXABAN | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | RIVAROXABAN | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.